Last 12 months
Inside the activity.
0 purchase rows · 29 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 9 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2019 Filed Feb 27, 2019 23:34 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
SaleCommon Stock | 336 | $88.23 | $29,645.28 |
DisclosureSEC source: 0001022079-19-000064 · wf-form4_155131043072799.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,772 F2 · shares: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 24, 2018. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:34 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Tax withholdingCommon Stock | 315 | $88.24 | $27,795.60 |
DisclosureSEC source: 0001022079-19-000064 · wf-form4_155131043072799.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,108 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:32 UTC |
Klug Robert AVP, Corporate Controller
|
Tax withholdingCommon Stock | 52 | $88.24 | $4,588.48 |
DisclosureSEC source: 0001022079-19-000062 · wf-form4_155131031587672.xml · nonDerivative · entry 1 Klug Robert A · CIK 0001347843 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,435 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:29 UTC |
GUINAN MARKExecutive Vice President & CFO
|
Tax withholdingCommon Stock | 660 | $88.24 | $58,238.40 |
DisclosureSEC source: 0001022079-19-000060 · wf-form4_155131017859571.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,125 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:27 UTC |
EGLINTON MANNER CARRIESVP, Advanced Diagnostics
|
Tax withholdingCommon Stock | 363 | $88.24 | $32,031.12 |
DisclosureSEC source: 0001022079-19-000058 · wf-form4_155131005992772.xml · nonDerivative · entry 1 EGLINTON MANNER CARRIE · CIK 0001696776 · SVP, Advanced Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,793 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:25 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
Tax withholdingCommon Stock | 363 | $88.24 | $32,031.12 |
DisclosureSEC source: 0001022079-19-000056 · wf-form4_155130990758300.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,590 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:22 UTC |
Davis J. E.EVP, General Diagnostics
|
Tax withholdingCommon Stock | 547 | $88.24 | $48,267.28 |
DisclosureSEC source: 0001022079-19-000054 · wf-form4_155130976041595.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,528 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:19 UTC |
Cunningham EverettSVP, Commercial
|
SaleCommon Stock | 326 | $88.23 | $28,762.98 |
DisclosureSEC source: 0001022079-19-000052 · wf-form4_155130957438717.xml · nonDerivative · entry 2 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,867 F2 · shares: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 31, 2018. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:19 UTC |
Cunningham EverettSVP, Commercial
|
Tax withholdingCommon Stock | 431 | $88.24 | $38,031.44 |
DisclosureSEC source: 0001022079-19-000052 · wf-form4_155130957438717.xml · nonDerivative · entry 1 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,193 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 20:08 UTC |
WILENSKY GAIL RDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 8,000 | $51.55 Strike: $51.55 | $412,400.00 |
DisclosureSEC source: 0001022079-19-000050 · wf-form4_155114330739944.xml · derivative · entry 3 WILENSKY GAIL R · CIK 0001018538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2019-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 20:08 UTC |
WILENSKY GAIL RDirector
|
SaleCommon Stock | 8,000 | $87.78 | $702,216.00 |
DisclosureSEC source: 0001022079-19-000050 · wf-form4_155114330739944.xml · nonDerivative · entry 2 WILENSKY GAIL R · CIK 0001018538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,604 F1 · price: This transaction was executed in multiple trades at prices ranging from $87.77 to $87.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2019 Filed Feb 25, 2019 20:08 UTC |
WILENSKY GAIL RDirector
|
Exercise / conversionCommon Stock | 8,000 | $51.55 | $412,400.00 |
DisclosureSEC source: 0001022079-19-000050 · wf-form4_155114330739944.xml · nonDerivative · entry 1 WILENSKY GAIL R · CIK 0001018538 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 01:06 UTC |
Klug Robert AVP, Corporate Controller
|
Tax withholdingCommon Stock | 50 | $88.39 | $4,419.50 |
DisclosureSEC source: 0001022079-19-000048 · wf-form4_155114315824117.xml · nonDerivative · entry 1 Klug Robert A · CIK 0001347843 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,487 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 01:04 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, President and CEO
|
Tax withholdingCommon Stock | 2,215 | $88.39 | $195,783.85 |
DisclosureSEC source: 0001022079-19-000047 · wf-form4_155114303022201.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,400 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 00:58 UTC |
GUINAN MARKExecutive Vice President & CFO
|
Tax withholdingCommon Stock | 610 | $88.39 | $53,917.90 |
DisclosureSEC source: 0001022079-19-000042 · wf-form4_155114267401719.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,785 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 01:01 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Tax withholdingCommon Stock | 291 | $88.39 | $25,721.49 |
DisclosureSEC source: 0001022079-19-000045 · wf-form4_155114288184638.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,423 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 00:55 UTC |
EGLINTON MANNER CARRIESVP, Advanced Diagnostics
|
Tax withholdingCommon Stock | 392 | $88.39 | $34,648.88 |
DisclosureSEC source: 0001022079-19-000040 · wf-form4_155114252046058.xml · nonDerivative · entry 1 EGLINTON MANNER CARRIE · CIK 0001696776 · SVP, Advanced Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,156 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 00:53 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
Tax withholdingCommon Stock | 336 | $88.39 | $29,699.04 |
DisclosureSEC source: 0001022079-19-000038 · wf-form4_155114241191010.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,953 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 00:40 UTC |
Davis J. E.EVP, General Diagnostics
|
Tax withholdingCommon Stock | 506 | $88.39 | $44,725.34 |
DisclosureSEC source: 0001022079-19-000036 · wf-form4_155114160824854.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,075 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 00:36 UTC |
Cunningham EverettSVP, Commercial
|
Tax withholdingCommon Stock | 398 | $88.39 | $35,179.22 |
DisclosureSEC source: 0001022079-19-000034 · wf-form4_155114139123355.xml · nonDerivative · entry 1 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,624 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:26 UTC |
GUINAN MARKExecutive Vice President & CFO
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 63,259 | $0.00 Strike: $86.63 | $0.00 |
DisclosureSEC source: 0001022079-19-000022 · wf-form4_155070518922803.xml · derivative · entry 2 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,259 Underlying: Common Stock · 63,259 shares Expires 2029-02-18 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:26 UTC |
GUINAN MARKExecutive Vice President & CFO
|
GrantCommon Stock | 5,195 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000022 · wf-form4_155070518922803.xml · nonDerivative · entry 1 GUINAN MARK · CIK 0001505998 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,395 F1 · shares: Represents an award of restricted share units. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:44 UTC |
MORRISON DENISE MDirector
|
GrantPhantom Stock Units · Derivative | 163 | $86.63 Strike: $0.00 | $14,120.69 |
DisclosureSEC source: 0001022079-19-000028 · wf-form4_155070624899918.xml · derivative · entry 2 MORRISON DENISE M · CIK 0001230166 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163 Underlying: Common Stock · 163 shares Expires not disclosed F2 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F2 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:44 UTC |
MORRISON DENISE MDirector
|
GrantCommon Stock | 484 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000028 · wf-form4_155070624899918.xml · nonDerivative · entry 1 MORRISON DENISE M · CIK 0001230166 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 484 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:33 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, President and CEO
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 213,704 | $0.00 Strike: $86.63 | $0.00 |
DisclosureSEC source: 0001022079-19-000026 · wf-form4_155070558946491.xml · derivative · entry 2 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,704 Underlying: Common Stock · 213,704 shares Expires 2029-02-18 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:33 UTC |
RUSCKOWSKI STEPHEN HDirector · Chairman, President and CEO
|
GrantCommon Stock | 17,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000026 · wf-form4_155070558946491.xml · nonDerivative · entry 1 RUSCKOWSKI STEPHEN H · CIK 0001142624 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,615 F1 · shares: Represents an award of restricted share units. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:32 UTC |
Klug Robert AVP, Corporate Controller
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 4,212 | $0.00 Strike: $86.63 | $0.00 |
DisclosureSEC source: 0001022079-19-000025 · wf-form4_155070552886230.xml · derivative · entry 2 Klug Robert A · CIK 0001347843 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,212 Underlying: Common Stock · 4,212 shares Expires 2029-02-18 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:32 UTC |
Klug Robert AVP, Corporate Controller
|
GrantCommon Stock | 347 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000025 · wf-form4_155070552886230.xml · nonDerivative · entry 1 Klug Robert A · CIK 0001347843 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,537 F1 · shares: Represents an award of restricted share units. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:30 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 35,146 | $0.00 Strike: $86.63 | $0.00 |
DisclosureSEC source: 0001022079-19-000024 · wf-form4_155070542873347.xml · derivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,146 Underlying: Common Stock · 35,146 shares Expires 2029-02-18 F4 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:30 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
GrantCommon Stock | 2,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000024 · wf-form4_155070542873347.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,714 F1 · shares: Represents an award of restricted share units. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:28 UTC |
EGLINTON MANNER CARRIESVP, Advanced Diagnostics
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 49,200 | $0.00 Strike: $86.63 | $0.00 |
DisclosureSEC source: 0001022079-19-000023 · wf-form4_155070532368222.xml · derivative · entry 2 EGLINTON MANNER CARRIE · CIK 0001696776 · SVP, Advanced Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,200 Underlying: Common Stock · 49,200 shares Expires 2029-02-18 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:28 UTC |
EGLINTON MANNER CARRIESVP, Advanced Diagnostics
|
GrantCommon Stock | 4,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000023 · wf-form4_155070532368222.xml · nonDerivative · entry 1 EGLINTON MANNER CARRIE · CIK 0001696776 · SVP, Advanced Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,548 F1 · shares: Represents an award of restricted share units. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:20 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 40,765 | $0.00 Strike: $86.63 | $0.00 |
DisclosureSEC source: 0001022079-19-000021 · wf-form4_155070483638553.xml · derivative · entry 3 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,765 Underlying: Common Stock · 40,765 shares Expires 2029-02-18 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:20 UTC |
Doherty Catherine T.SVP, Group Exec. Clin. Fran.
|
GrantCommon Stock | 3,348 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000021 · wf-form4_155070483638553.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · SVP, Group Exec. Clin. Fran. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,289 F1 · shares: Represents an award of restricted share units. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:13 UTC |
Cunningham EverettSVP, Commercial
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 40,765 | $0.00 Strike: $86.63 | $0.00 |
DisclosureSEC source: 0001022079-19-000019 · wf-form4_155070441642215.xml · derivative · entry 3 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,765 Underlying: Common Stock · 40,765 shares Expires 2029-02-18 F4 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:13 UTC |
Cunningham EverettSVP, Commercial
|
GrantCommon Stock | 3,348 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000019 · wf-form4_155070441642215.xml · nonDerivative · entry 1 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,022 F1 · shares: Represents an award of restricted share units. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:17 UTC |
Davis J. E.EVP, General Diagnostics
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 60,450 | $0.00 Strike: $86.63 | $0.00 |
DisclosureSEC source: 0001022079-19-000020 · wf-form4_155070463311392.xml · derivative · entry 2 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,450 Underlying: Common Stock · 60,450 shares Expires 2029-02-18 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 18, 2019 Filed Feb 20, 2019 23:17 UTC |
Davis J. E.EVP, General Diagnostics
|
GrantCommon Stock | 4,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-19-000020 · wf-form4_155070463311392.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · EVP, General Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,581 F1 · shares: Represents an award of restricted share units. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:37 UTC |
RING TIMOTHY MDirector
|
GrantPhantom Stock Units · Derivative | 376 | $82.00 Strike: $0.00 | $30,830.12 |
DisclosureSEC source: 0001022079-19-000004 · wf-form4_154655145311396.xml · derivative · entry 1 RING TIMOTHY M · CIK 0001204666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,585.231 Underlying: Common Stock · 376 shares Expires not disclosed F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F2 · balance_after: Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:36 UTC |
EGLINTON MANNER CARRIESVP, Advanced Diagnostics
|
Tax withholdingCommon Stock | 1,767 | $82.27 | $145,371.09 |
DisclosureSEC source: 0001022079-19-000003 · wf-form4_154655136928135.xml · nonDerivative · entry 1 EGLINTON MANNER CARRIE · CIK 0001696776 · SVP, Advanced Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,507 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| October 12, 2018 Filed Oct 16, 2018 20:33 UTC |
Klug Robert AVP, Corporate Controller
|
Tax withholdingCommon Stock | 8 | $100.51 | $804.08 |
DisclosureSEC source: 0001022079-18-000173 · wf-form4_153972198249048.xml · nonDerivative · entry 1 Klug Robert A · CIK 0001347843 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,972 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 22:53 UTC |
Torley HelenDirector
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 1,298 | $0.00 Strike: $108.35 | $0.00 |
DisclosureSEC source: 0001022079-18-000171 · wf-form4_153860720841402.xml · derivative · entry 1 Torley Helen · CIK 0001528185 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,298 Underlying: Common Stock · 1,298 shares Expires 2028-10-01 Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 22:48 UTC |
RING TIMOTHY MDirector
|
GrantPhantom Stock Units · Derivative | 284 | $108.35 Strike: $0.00 | $30,769.98 |
DisclosureSEC source: 0001022079-18-000169 · wf-form4_153860691952801.xml · derivative · entry 1 RING TIMOTHY M · CIK 0001204666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,174.141 Underlying: Common Stock · 284 shares Expires not disclosed F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F2 · balance_after: Total number of phantom stock units accrued as of the transaction date in the reporting person's deferred compensation account includes phantom stock units credited as a result of dividend reinvestment transactions exempt from reporting pursuant to Rule 16a-11. Read SEC document |
| August 17, 2018 Filed Aug 21, 2018 20:32 UTC |
Klug Robert AVP, Corporate Controller
|
Tax withholdingCommon Stock | 21 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-18-000165 · wf-form4_153488350607228.xml · nonDerivative · entry 1 Klug Robert A · CIK 0001347843 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,928 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted share units. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 20:53 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 30,780 | $57.61 Strike: $57.61 | $1,773,081.90 |
DisclosureSEC source: 0001022079-18-000155 · wf-form4_153142881491793.xml · derivative · entry 4 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,780 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on June 4, 2018. F5 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on February 27, 2013, the second on February 27, 2014 and the final on February 27, 2015. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 20:53 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
SaleCommon Stock | 30,780 | $113.07 | $3,480,140.70 |
DisclosureSEC source: 0001022079-18-000155 · wf-form4_153142881491793.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,791 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on June 4, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $113.00 to $113.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 20:53 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Exercise / conversionCommon Stock | 30,780 | $57.61 | $1,773,081.90 |
DisclosureSEC source: 0001022079-18-000155 · wf-form4_153142881491793.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on June 4, 2018. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 20:52 UTC |
Cunningham EverettSVP, Commercial
|
Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 40,328 | $71.17 Strike: $71.17 | $2,870,143.76 |
DisclosureSEC source: 0001022079-18-000153 · wf-form4_153142872668242.xml · derivative · entry 4 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,328 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 31, 2018. F4 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 23, 2016, the second on February 23, 2017 and the final on February 23, 2018. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 20:52 UTC |
Cunningham EverettSVP, Commercial
|
SaleCommon Stock | 40,328 | $112.00 | $4,516,736.00 |
DisclosureSEC source: 0001022079-18-000153 · wf-form4_153142872668242.xml · nonDerivative · entry 2 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,261 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 31, 2018. F2 · balance_after: The amount includes exempt purchases made under the Company's stock purchase plan. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 20:52 UTC |
Cunningham EverettSVP, Commercial
|
Exercise / conversionCommon Stock | 40,328 | $71.17 | $2,870,143.76 |
DisclosureSEC source: 0001022079-18-000153 · wf-form4_153142872668242.xml · nonDerivative · entry 1 Cunningham Everett · CIK 0001564777 · SVP, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 31, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.